EPS Bio Technology Corp. appears in FDA premarket records as the applicant for glucose test systems regulated under 21 CFR 862.1345, product code NBW, in Class II. The most recent record in the collection is K261293, received April 20, 2026, and decided October 23, 2026, as substantially equivalent under a Special 510(k) pathway. The filing names the EASYMAX Voice Blood Glucose Monitoring System and lists a Hsinchu, Taiwan, filing address. Earlier records in the numbered sources cover the EASYMAX Tag Self-Monitoring Blood Glucose System. [1][2][7]
The 2026 EASYMAX Voice clearance
FDA record K261293 identifies the EASYMAX Voice Blood Glucose Monitoring System as a Class II over-the-counter blood glucose test system, regulation number 862.1345, product code NBW, with Clinical Chemistry as the advisory committee. The decision code is SESE, described as Substantially Equivalent, with a decision date of October 23, 2026, and a Special clearance type. The submission was received April 20, 2026, and the third-party review flag is marked N. [1]
The decision document for K261293 repeats the applicant name and the proprietary and established name EASYMAX Voice Blood Glucose Monitoring System. The FDA letter dated October 23, 2026, is signed by Joshua M. Balsam, Ph.D., Branch Chief, Division of Chemistry and Toxicology Devices, within the Office of In Vitro Diagnostics. The record indicates a Summary was prepared rather than a statement. [2][5][1]
Earlier EASYMAX Tag filing
An earlier FDA record, K201258, covers the EASYMAX Tag Self-Monitoring Blood Glucose System, also under regulation 21 CFR 862.1345, Class II, product code NBW. The FDA letter is dated September 1, 2021, and the submission is described as a Special 510(k). The listed contact is Steve Tseng, QA Manager, at the Hsinchu Science Park address. [7]
The FDA over-the-counter device listing for K201258 names the test as the EPS Bio Technology Corp. EasyMax Tag Self-Monitoring Blood Glucose System and the manufacturer as Eps Bio Technology Corp. The 510(k) summary enclosure for K201258 carries the company name EPS Bio Technology Corp. and the same Hsinchu address, with telephone and fax numbers and a company email contact. [6][7]
Published product description
EPS Bio Technology Corp.’s own published post describes the Voice as combining a meter and voice output module in one device, with voice output intended as a benefit for users who are visually impaired or blind. The post states that users can choose a language among English, Spanish, Arabic, French, or additional options, and it is dated October 10, 2021, with an update noted April 26, 2024. These are manufacturer statements about the product, not FDA findings of performance. [3]
The company’s website describes EPS Bio as active in regulatory professionals, certified system, engineering resources and clinical suggestions for customers, and states that it has commercialized value-added products for glucose meters. The site lists an address at No.8, R&D RD III, Hsinchu Science Park, Hsinchu County, Taiwan 30076, with telephone, fax and email contacts. These are company-published descriptions. [4]
What the records establish and what they do not
The collection linked as of November 20, 2026, contains one 510(k) record, K261293, with a decision count of one SESE. The record sample is the same single entry, so the sample decision count is also one SESE. These figures describe the linked filings at that date and are not measures of total company sales, total portfolio or safety performance. [1]
The numbered sources do not establish ownership, parentage, headquarters, customers, commercial availability or clinical performance for the EASYMAX Voice system. The Hsinchu address appears in FDA filing records and company pages as a contact address; it is not treated here as a verified headquarters. Any detail beyond the named products, regulation, product code, decision dates and published descriptions remains unknown. [1][4][7]

